Stay updated on Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial
Sign up to get notified when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.

Latest updates to the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedDate entries were added (2026-03-31, 2020-04-02, 2026-03-13, 2026-03) and several related-topic items, including 'Multiple myeloma' and 'MedlinePlus Genetics', were removed.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page. This reflects a new page version being published.SummaryDifference0.0%

- Check34 days agoChange DetectedAdded related topics: Multiple myeloma and MedlinePlus Genetics to the page. This provides contextual information about the disease and access to genetics resources for readers.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check48 days agoChange DetectedRelated topics links for Multiple Myeloma and MedlinePlus Genetics were removed from the page.SummaryDifference0.1%

- Check62 days agoChange DetectedThe DREAMM-3 study locations were updated to add and remove sites, with the page now indicating 102 locations (including Omaha, NE and Shibuya-Ku, Tokyo) and a revision to version 3.4.2.SummaryDifference2%

Stay in the know with updates to Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.